SQI Diagnostics Inc. (SQIDF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SQI Diagnostics Inc. (SQIDF) with AI Score 64/100 (Hold). SQI Diagnostics Inc. is a precision medicine company focused on developing and commercializing rapid diagnostic testing services. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026SQI Diagnostics Inc. (SQIDF) Healthcare & Pipeline Overview
SQI Diagnostics Inc. operates within the precision medicine sector, providing rapid diagnostic testing services and products globally. The company's offerings include lung health assessments, COVID-19 tests, and antibody testing solutions, positioning it as a player in the evolving diagnostics landscape.
Investment Thesis
SQI Diagnostics Inc. presents a speculative investment opportunity within the precision medicine and diagnostics sector. With a market capitalization of $0.01 billion and a negative P/E ratio of -0.43, the company's financial performance indicates it is currently not profitable. The gross margin of 38.3% suggests potential in its core offerings, but the negative profit margin of -228.6% highlights significant operational challenges. Key catalysts include the potential for increased adoption of its COVID-19 testing solutions and expansion of its lung health assessment product, TOR-dx. However, the company's negative beta of -0.36 suggests a potential disconnect from broader market movements, and its lack of dividend yield may deter some investors. The company's ability to achieve profitability and effectively commercialize its diagnostic products will be critical to its long-term success.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 38.3% demonstrates the potential profitability of its diagnostic products before operating expenses.
- Negative Profit Margin of -228.6% highlights significant challenges in achieving overall profitability.
- Beta of -0.36 suggests the stock price moves inversely to the market, potentially offering diversification benefits.
- The company offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung.
Competitors & Peers
Strengths
- Proprietary diagnostic technologies.
- Focus on rapid and point-of-care testing.
- Portfolio of COVID-19 related tests.
- Expertise in precision medicine.
Weaknesses
- Negative profit margin and limited financial resources.
- Dependence on a limited number of products.
- Competition from larger, more established players.
- OTC market listing.
Catalysts
- Potential regulatory approvals for new diagnostic tests.
- Expansion of distribution channels for COVID-19 testing solutions.
- Partnerships with healthcare organizations and research institutions.
- Publication of clinical data supporting the efficacy of TOR-dx lung test.
Risks
- Regulatory hurdles and reimbursement challenges.
- Competition from larger, more established players.
- Dependence on a limited number of products.
- Technological obsolescence.
- Limited financial resources and negative profit margin.
Growth Opportunities
- Expansion of COVID-19 Testing Solutions: SQI Diagnostics has the opportunity to capitalize on the ongoing need for COVID-19 testing solutions, including at-home antibody tests and severity triage tests. The global COVID-19 diagnostics market was valued at billions in 2025 and is expected to continue to grow, driven by new variants and the need for ongoing monitoring. By expanding its distribution channels and developing more advanced testing technologies, SQI Diagnostics can increase its market share and generate revenue growth.
- Adoption of TOR-dx Lung Test: The TOR-dx lung test offers a valuable tool for surgeons assessing the health of donor lungs, potentially improving transplant outcomes. The market for lung transplant diagnostics is growing, driven by increasing rates of lung disease and the need for more effective transplant procedures. By partnering with transplant centers and demonstrating the clinical benefits of TOR-dx, SQI Diagnostics can drive adoption and establish itself as a leader in lung transplant diagnostics.
- Development of New Diagnostic Tests: SQI Diagnostics can leverage its expertise in precision medicine to develop new diagnostic tests for other diseases and conditions. The market for diagnostic testing is vast and growing, with opportunities in areas such as cancer, cardiovascular disease, and infectious diseases. By investing in research and development and partnering with academic institutions and other companies, SQI Diagnostics can expand its product portfolio and address unmet needs in the healthcare market.
- Strategic Partnerships and Acquisitions: SQI Diagnostics can accelerate its growth by forming strategic partnerships with other companies in the healthcare industry. These partnerships can provide access to new markets, technologies, and distribution channels. Additionally, SQI Diagnostics could consider acquiring smaller companies with complementary technologies or products to expand its capabilities and market reach. Strategic partnerships and acquisitions can help SQI Diagnostics to achieve its growth objectives more quickly and efficiently.
- Expansion into International Markets: SQI Diagnostics has the opportunity to expand its operations into international markets, particularly in Europe and Asia. These markets offer significant growth potential, driven by increasing healthcare spending and the adoption of new diagnostic technologies. By establishing a presence in these markets and adapting its products to local needs, SQI Diagnostics can diversify its revenue streams and reduce its reliance on the North American market.
Opportunities
- Expansion into new diagnostic testing markets.
- Strategic partnerships and acquisitions.
- Increased adoption of point-of-care testing.
- Growth in international markets.
Threats
- Regulatory changes and reimbursement challenges.
- Technological obsolescence.
- Competition from new entrants.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary diagnostic technologies and intellectual property.
- Established relationships with healthcare providers and research institutions.
- Expertise in precision medicine and rapid diagnostics.
- First-mover advantage in certain diagnostic testing markets.
About SQIDF
Founded in 1999 and headquartered in Toronto, Canada, SQI Diagnostics Inc. is a precision medicine company dedicated to discovering, developing, and commercializing rapid diagnostic testing services. The company serves healthcare providers, patients, and consumers worldwide. SQI Diagnostics' product portfolio includes TOR-dx, a lung test designed to assess the health of donor lungs during transplant procedures, and a suite of COVID-19 related tests, including an at-home antibody test kit, the RALI-Dx, a lab-based COVID-19 severity triage test, and RALI-fast, a point-of-care COVID-19 severity triage test. These tests aim to provide rapid and actionable insights for healthcare decision-making. Additionally, SQI Diagnostics offers microarray instruments used in antibody testing workflows, providing tools for research and diagnostic applications. The company's focus on precision medicine and rapid diagnostics reflects a broader trend in healthcare towards personalized and timely interventions.
What They Do
- Develops and commercializes rapid diagnostic testing services.
- Offers lung health assessment tests (TOR-dx).
- Provides COVID-19 at-home antibody test kits.
- Offers lab-based (RALI-Dx) and point-of-care (RALI-fast) COVID-19 severity triage tests.
- Manufactures microarray instruments for antibody testing workflows.
- Serves healthcare providers, patients, and consumers globally.
Business Model
- Sales of diagnostic testing services to healthcare providers and patients.
- Sales of diagnostic test kits directly to consumers.
- Sales of microarray instruments to research institutions and diagnostic labs.
- Partnerships with healthcare organizations for test development and distribution.
Industry Context
SQI Diagnostics operates in the medical diagnostics and research industry, a sector experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market is competitive, with established players like BCBCF (BioCanCell Therapeutics), BLMHF (BioLife Solutions Inc), CLSH (Clash Therapeutics), DOCRF (Docrates Health Corporation), and DTXMF (Datametrex AI Limited) vying for market share. Trends include the rise of point-of-care diagnostics, the integration of AI and machine learning, and the increasing importance of data analytics in healthcare. SQI Diagnostics' focus on rapid diagnostic testing services aligns with these trends, but the company faces challenges in scaling its operations and competing with larger, more established players.
Key Customers
- Healthcare providers (hospitals, clinics, and physicians).
- Patients seeking diagnostic testing services.
- Research institutions and diagnostic laboratories.
- Consumers purchasing at-home test kits.
Financials
Chart & Info
SQI Diagnostics Inc. (SQIDF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SQIDF.
Price Targets
Wall Street price target analysis for SQIDF.
MoonshotScore
What does this score mean?
The MoonshotScore rates SQIDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andrew Morris
CEO
Andrew Morris is the CEO of SQI Diagnostics Inc. His background includes experience in the healthcare and diagnostics industries. He has held various leadership roles in companies focused on developing and commercializing innovative medical technologies. His expertise spans strategic planning, business development, and commercial operations. He is responsible for leading SQI Diagnostics' overall strategy and execution.
Track Record: Under Andrew Morris' leadership, SQI Diagnostics has focused on expanding its portfolio of diagnostic testing services and products, including COVID-19 tests and lung health assessments. He has overseen the development and commercialization of new diagnostic technologies and has worked to establish partnerships with healthcare organizations and research institutions. His focus has been on driving revenue growth and improving the company's financial performance.
SQIDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that SQI Diagnostics Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the potential for lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Going concern risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Established history of operations since 1999.
- Focus on precision medicine and diagnostics.
- Portfolio of diagnostic testing services and products.
- Presence in the healthcare sector.
What Investors Ask About SQI Diagnostics Inc. (SQIDF) — Healthcare
What does SQI Diagnostics Inc. do?
SQI Diagnostics Inc. is a precision medicine company focused on developing and commercializing rapid diagnostic testing services and products. The company offers a range of diagnostic solutions, including the TOR-dx lung test for assessing donor lung health, COVID-19 at-home antibody test kits, and RALI-Dx and RALI-fast COVID-19 severity triage tests. Additionally, SQI Diagnostics provides microarray instruments for antibody testing workflows, serving healthcare providers, patients, and consumers worldwide. The company's focus is on providing rapid and actionable insights for healthcare decision-making.
What do analysts say about SQIDF stock?
As of 2026-03-17, there is no readily available analyst consensus on SQIDF stock, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio, indicate the company is currently not profitable. Growth considerations include the potential for increased adoption of its COVID-19 testing solutions and expansion of its lung health assessment product, TOR-dx. Investors should conduct their own thorough research and consider the risks associated with investing in micro-cap OTC stocks.
What are the main risks for SQIDF?
The main risks for SQIDF include its OTC market listing, which entails limited financial disclosure and regulatory oversight. The company's negative profit margin and limited financial resources pose challenges to its long-term viability. Competition from larger, more established players in the diagnostics industry is also a significant risk. Additionally, regulatory hurdles, reimbursement challenges, and the potential for technological obsolescence could impact the company's ability to achieve its growth objectives. Investors should carefully consider these risks before investing in SQIDF.
What are the key factors to evaluate for SQIDF?
SQI Diagnostics Inc. (SQIDF) currently holds an AI score of 64/100, indicating moderate score. Key strength: Proprietary diagnostic technologies. Primary risk to monitor: Regulatory hurdles and reimbursement challenges. This is not financial advice.
How frequently does SQIDF data refresh on this page?
SQIDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SQIDF's recent stock price performance?
Recent price movement in SQI Diagnostics Inc. (SQIDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary diagnostic technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SQIDF overvalued or undervalued right now?
Determining whether SQI Diagnostics Inc. (SQIDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SQIDF?
Before investing in SQI Diagnostics Inc. (SQIDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.